SARS-CoV-2 Serology Did Not Predict Risk of Breakthrough Infection During the Omicron BA.1 and BA.2 Surge.

The article discusses research which examined the use of SARS-CoV-2 serology to assess risk of SARS-CoV-2 breakthrough infection (BTI) after COVID-19 vaccination during the omicron surge. The study measured serology and identified BTI from weekly saliva self-collection. It describes the demographics and clinical characteristics prior to index date, COVID-19 vaccination, and SARS-CoV-2 BTI by anti-nucleocapsid and anti-spike protein receptor-binding domain serology results.